The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) on 2017-02-02. This approval, designated as a supplemental Biologics License Application (BLA 125554 S-24), was granted based on efficacy data.
Background
Nivolumab, known commercially as Opdivo, is a pharmaceutical product developed and marketed by Bristol Myers Squibb. The FDA's action on 2017-02-02 involved a supplemental application, which means the approval expanded upon an existing marketing authorization for the drug. This particular supplemental approval was categorized under "Efficacy," indicating that the FDA reviewed new clinical data demonstrating the drug's effectiveness for an additional use or in a new patient population. Such approvals are critical for broadening the therapeutic scope of established medications.
What this means
The FDA's approval of a supplemental application for Opdivo (nivolumab) based on efficacy data on 2017-02-02 represents an expansion of the drug's approved indications or patient populations. A supplemental application is typically submitted when a manufacturer seeks to modify an existing approval, such as adding a new use, changing the dosage, or updating safety information. In this case, the "Efficacy" class of the approval confirms that new clinical evidence was presented and accepted by the FDA, demonstrating that nivolumab is safe and effective for an additional purpose. This action provides healthcare providers with more options for utilizing Opdivo in patient treatment plans, potentially offering benefits to a wider range of individuals. For patients, it means that nivolumab is now officially recognized by the FDA for an expanded set of conditions or circumstances, backed by scientific evidence of its effectiveness. This continuous process of supplemental approvals allows drugs like nivolumab to evolve in their clinical application as new research emerges, ensuring that approved treatments remain current with scientific advancements and patient needs.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Biologics License Application (BLA) 125554 S-24, pertaining to Opdivo (nivolumab), was recorded on 2017-02-02 on accessdata.fda.gov.